Free tool
FAERS Monitor: Stiolto Respimat
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206756 or its brand name (Stiolto Respimat, Olodaterol Hydrochloride, Tiotropium Bromide). Reports on generic versions are filed under their own applications.
Reports
5,135
Serious
1,966
38% of reports
Hospitalization
1,071
Death reported
373
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea934
- cough422
- drug ineffective345
- off label use304
- fatigue254
- headache245
- death230
- diarrhoea219
- pneumonia218
- chronic obstructive pulmonary disease207
- nausea193
- dizziness192
- product quality issue170
- asthenia140
- fall137
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2015 | 185 |
| 2016 | 423 |
| 2017 | 539 |
| 2018 | 479 |
| 2019 | 428 |
| 2020 | 480 |
| 2021 | 434 |
| 2022 | 424 |
| 2023 | 408 |
| 2024 | 444 |
| 2025 | 473 |
| 2026 | 417 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,024 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic obstructive pulmonary diseaseSignal | 207 | 16.3 | 14.3 | 2,955 |
| dyspnoeaSignal | 934 | 6.8 | 6.4 | 4,704 |
| coughSignal | 422 | 6.2 | 5.6 | 1,845 |
| product quality issueSignal | 170 | 5.1 | 4.4 | 564 |
| pneumoniaSignal | 218 | 2.8 | 2.4 | 246 |
| fall | 137 | 1.7 | 1.4 | 38 |
| headache | 245 | 1.6 | 1.4 | 56 |
| dizziness | 192 | 1.6 | 1.4 | 41 |
| asthenia | 140 | 1.5 | 1.3 | 25 |
| off label use | 304 | 1.4 | 1.3 | 39 |
| diarrhoea | 219 | 1.4 | 1.2 | 24 |
| fatigue | 254 | 1.3 | 1.2 | 22 |
| death | 230 | 1.1 | 1.0 | 2 |
| drug ineffective | 345 | 1.1 | 1.0 | 2 |
| nausea | 193 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.